If you have been reading about glucagon receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-28. Numbers and descriptions here follow the published literature rather than marketing material.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
The National Economic Council (NEC) in Pakistan is a constitutional entity tasked with evaluating the nation's economic state and devising strategies to promote equitable development and regional balance. Functioning within the framework of Article 156 of the Constitution of Pakistan, it plays a vital advisory role to both federal and provincial governments on matters pertaining to finance, commerce, social welfare, and economic policies.
=== Euthanasia === Approved procedures for euthanasia of laboratory mice include compressed CO2 gas, injectable barbiturate anesthetics, inhalable anesthetics, such as Halothane, and physical methods, such as cervical dislocation and decapitation. In 2013, the American Veterinary Medical Association issued new guidelines for CO2 induction, stating that a flow rate of 10% to 30% volume/min is optimal for euthanasing laboratory mice.
Christians constitute the majority of the city's population, most of whom follow the Russian Orthodox Church. The Patriarch of Moscow serves as the head of the Church and lives in the Danilov Monastery. Moscow was called the "city of 40 times 40 churches"—before the Russian Revolution in 1917. Moscow is Russia's capital of Eastern Orthodox Christianity, which has been the country's traditional religion. Other religions practiced in Moscow include Buddhism, Hinduism, Islam, Judaism, Yazidism, and Rodnovery (Slavic Native Faith). The Moscow Mufti Council claimed that Muslims numbered around 1.5 million of the city's 10.5 million population in 2010. The city has four mosques.
Glutathione has antioxidant properties since the thiol group in its cysteine moiety is a reducing agent and can be reversibly oxidized and reduced. In cells, glutathione is maintained in the reduced form by the enzyme glutathione reductase and in turn reduces other metabolites and enzyme systems, such as ascorbate in the glutathione-ascorbate cycle, glutathione peroxidases and glutaredoxins, as well as reacting directly with oxidants. Due to its high concentration and its central role in maintaining the cell's redox state, glutathione is one of the most important cellular antioxidants. In some organisms glutathione is replaced by other thiols, such as by mycothiol in the Actinomycetes, bacillithiol in some gram-positive bacteria, or by trypanothione in the Kinetoplastids. A derivative of glutathione, glutathione hydropersulfide, operates as an abundant radical-trapping antioxidant with greater potency against free radical oxidation than glutathione itself.
Sources: en.wikipedia.org
Docks Océane is a multi-purpose hall (concerts, shows, and sporting events) which can accommodate up to 4,700 spectators in 1,800 square metres (19,000 sq ft). The largest cinema in Le Havre is located on the Docks Vauban (2,430 seats). The Docks Café is an exhibition centre of 17,500 square metres (188,000 sq ft) used for shows, fairs, and exhibitions. The Magic Mirrors offers many concerts managed by the city and leased to private organizers. Following the closure of Cabaret Electric which was located in the Espace Oscar Niemeyer in 2011 a new auditorium, Le Tetris, is under construction at the Fort of Tourneville. It was scheduled to open in September 2013 with a large festival free-of-charge. It will consist of two halls with 800 and 200 seats, exhibition space, housing for artists in residence, a restaurant etc. Le Tetris will be a venue for contemporary music as well as theatre, dance, and visual arts. An "expectation" outside the walls was held on the site of the fort during 2012 and early 2013.
== Advantages == The B1H system has significant advantages over other methods that investigate protein–DNA interactions. Microarray-based readout of chromatin immunoprecipitation (ChIP-chip) for high-throughput binding-site determination relies on specific antibodies which may not always be available. Methods that rely on protein-binding microarrays also require additional protein purification steps that are not required in the B1H system. Furthermore, these microarray-based techniques are often prohibitive in terms of requiring special facilities and expertise to analyze the resulting data. SELEX, another system commonly used to identify the target nucleic acids for DNA-binding proteins, requires multiple rounds of selection. In contrast, the bacterial one-hybrid system requires just one round of in vitro selection and also offers a low-tech alternative to microarray-based technologies. Antibodies are not required for studying the interactions of DNA-binding proteins in the B1H system. A further advantage is that the B1H system works not only for monomeric proteins but also for proteins that bind DNA as complexes. The B1H system should be considered a specialized technique for studying DNA-protein interactions whereas the two-hybrid variations (B2H and Y2H) can assess both protein–protein and protein–DNA interactions. These two-hybrid systems are multi-purpose but are limited in terms of assaying only a single “prey” library.
These require urgent assessment for rhabdomyolysis as in about 30% of cases this leads to acute kidney injury, which left untreated can be life-threatening. In a small number of cases compartment syndrome has developed, requiring prompt surgical referral.
Big Tobacco: How the States Took on the Cigarette Giants (1998) online Sivulka, Juliann. Soap, Sex, and Cigarettes: A Cultural History of American Advertising (2nd ed. 2012) online Sobel, Robert. They satisfy: the cigarette in American life (1978) online Sobel R (1974). "James Buchanan Duke: Opportunism Is the Spur". The Entrepreneurs: Explorations Within the American Business Tradition. New York: Weybright & Talley. ISBN 0-679-40064-8. Starks, Tricia. Cigarettes and Soviets: Smoking in the USSR (Cornell University Press, 2022) Starr, Michael E. "The Marlboro Man: Cigarette Smoking and Masculinity in America." Journal of Popular Culture 17 (1984): 45–57. Swanson, Drew A. A Golden Weed: Tobacco and Environment in the Piedmont South (Yale University Press, 2014) 360pp Tennant, Richard B. American Cigarette Industry: A Study in Economic Analysis and Public Policy (Yale UP, 1950) online Tennant, Richard B. "The Cigarette Industry" in The Structure of American Industry, edited by Walter Adams (1961) pp 357–392. online Tilley, Nannie M. The R.J. Reynolds tobacco company (UNC Press Books, 1985), covers history to 1963; part of American Tobacco Company 1899–191, then independent again. online Tilley, Nannie M. The bright-tobacco industry, 1860-1929 (1948) online Tilley, Nannie May. "Agitation Against the American Tobacco Company in North Carolina, 1890-1911." North Carolina Historical Review 24.2 (1947): 207–223. Wagner, Susan. Cigarette Country: Tobacco in American History and Politics (Praeger, 1971). online Wailoo, Keith.
== History == Fosfomycin (originally known as phosphonomycin) was discovered in a joint effort of Merck and Co. and Spain's Compañía Española de Penicilina y Antibióticos (CEPA). It was first isolated by screening broth cultures of Streptomyces fradiae isolated from soil samples for the ability to cause formation of spheroplasts by growing bacteria. The discovery was described in a series of papers published in 1969. CEPA began producing fosfomycin on an industrial scale in 1971 at its Aranjuez facility.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.